Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
4(80.0%)
N/A
1(20.0%)
5Total
Phase 4(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00169026Phase 4Terminated

Alcoholism and Schizophrenia: Effects of Clozapine

Role: collaborator

NCT00434980Not ApplicableCompleted

Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia

Role: collaborator

NCT00169091Phase 4Terminated

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

Role: collaborator

NCT00169065Phase 4Completed

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

Role: collaborator

NCT00169039Phase 4Terminated

Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia

Role: collaborator

All 5 trials loaded